• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

byMeagan WiedermanandMichael Pratte
December 9, 2021
in Emergency, Neurology
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

1. Treatment after a minor stroke or transient ischemic attack with dual anti-platelet therapy (DAPT), either clopidogrel with aspirin or ticagrelor with aspirin, similarly reduces the risk of stroke or death, which is more than treatment with aspirin alone.

2. Both DAPTs had a similar risk of major hemorrhage, 90-day mortality, and adverse event rates, but clopidogrel and aspirin had a superior decrease in risk of disability due to stroke.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Having a minor ischemic stroke or transient ischemic attack (TIA) is a risk factor for having a subsequent stroke. Short-term dual anti-platelet therapy (DAPT) using clopidogrel and acetylsalicylic acid (ASA; aspirin) or using ticagrelor and aspirin is known to be better than monotherapy for secondary stroke prevention after TIA. This study aimed to compare the efficacy and safety of the two DAPT protocols. This metanalysis compared recurrent stroke or death rates, functional disability via the modified Rankin Scale (mRS), and safety between ticagrelor and aspirin, clopidogrel and aspirin, and aspirin after TIA or minor stroke. Pooling the data between the 5 eligible randomized controlled trials (RCTs) and 4 subgroup analyses identified that using a DAPT was superior to aspirin alone at stroke or death prevention and the two DAPT protocols were similar at stroke or death prevention. Specifically, both DAPTs decreased the incidence of ischemic stroke, with clopidogrel having a superior effect.  Neither DAPT regimen increased the risk of hemorrhagic stroke.. Both DAPTs increased the risk of major hemorrhage. While both DAPTs and aspirin had similar 90-day mortality and adverse event rates, clopidogrel and aspirin were associated with a decreased risk of functional disability versus aspirin alone. One strength of this metanalysis is the a priori publication of the search strategy to reduce bias. Additionally, it featured net metanalysis, which could rank treatments, unlike other metanalysis. One consideration is that this metanalysis may have overlooked a significant portion of data by only including RCTs, though it can then claim causative relations. A limitation of this study is that treatment durations and follow-up time differed in the different included RCTs as did the inclusion and exclusion criteria, though minimally. Finally, there was no assessment of publication bias because of the net metanalysis method used.

Click to read the study in JAMA Neurology

Relevant Reading: Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA

In-Depth [systematic review and meta-analysis]: This metanalysis averaged the recurrent stroke or death rates at 90 days in RCTs that compared ticagrelor and aspirin, clopidogrel and aspirin, and aspirin use in adults within 72 hours of TIA or minor stroke. Additionally, it assessed functional disability via the mRS and adverse events. RCTs were found in English or French on MEDLINE, Embase, Cochrane Registry of Clinical Trials, the World Stroke Congress and International Stroke Conference and selected by two independent reviewers. Bias was assessed using the Cochrane Risk of Bias tool for randomized trials version 2 (RoB2). 5 RCTs and 4 subgroup analyses (N = 22,098; 10,722 received aspirin, 5,517 received clopidogrel and aspirin, and 5,859 received ticagrelor and aspirin) met the inclusion criteria out of the 4014 unique titles screened. The studies were all at low risk of bias by RoB2. 3 RCTs compared clopidogrel and aspirin to aspirin, 1 RCT compared ticagrelor and aspirin to aspirin, and 1 RCT compared clopidogrel and aspirin to ticagrelor and aspirin, all of similar doses for 21-90 days. The included RCTs included similarly aged participants and definitions of stroke. Consistent with previous studies, clopidogrel and aspirin were superior at preventing stroke or death than aspirin alone (HR = 0.74, 95% Credible Intervals (CrI) = 0.65-0.84), as was ticagrelor and aspirin (HR = 0.79, 95% CrI = 0.68-0.91). Clopidogrel and aspirin were similar to ticagrelor and aspirin at stroke and death prevention (HR = 0.94, 95% CrI = 0.78-1.13). Compared to aspirin alone, clopidogrel and aspirin (HR = 0.71; 95% CrI = 0.62-0.82) and ticagrelor and aspirin (OR = 0.74, 95% CrI = 0.64-0.86) both reduced recurrent ischemic stroke. Clopidogrel performed best on surface under the cumulative rank curve (SUCRA) while aspirin alone had the highest risk for ischemic stroke and death prevention. Neither DAPT protocol increased the risk of hemorrhagic stroke compared to aspirin, nor compared to each other (HR = 0.67, 95% CrI = 0.26-1.70). Ticagrelor and aspirin had the highest risk of hemorrhagic stroke by SUCRA. Both DAPT protocols increased the risk of major hemorrhage compared to aspirin alone (clopidogrel: HR = 1.78, 95% CrI = 1.09-2.92; ticagrelor: HR = 2.63, 95%CrI = 1.51-4.82). Clopidogrel and aspirin had lower disability risk compared to aspirin alone (HR = 0.82; 95% CrI = 0.74-0.91) and compared to ticagrelor and aspirin (HR = 0.85, 95% CrI = 0.75-0.97). All of the treatments had comparable 90-day mortality, though ticagrelor and aspirin had the highest SUCRA, as well as highest rate of adverse events. There was no statistically significant difference in reduction of stroke or death on sensitivity analysis between treatment after a minor stroke or TIA with clopidogrel and aspirin compared with ticagrelor and aspirin (HR = 0.83, 95% CrI, 0.68-1.02); clopidogrel and aspirin had the lowest risk of stroke recurrence by SUCRA (0.96) compared to ticagrelor and aspirin (0.4) and aspiring (0).

RELATED REPORTS

Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke

POINT trial: Clopidogrel and Aspirin for Acute Ischemic Stroke [Classics Series]

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: clopidogreldual anti-platelet therapy (DAPT)TIATicagrelorTransient Ischemic Attack (TIA)
Previous Post

Recent trends in stroke severity, unfavourable outcomes, and mortality compared by sex

Next Post

Mental health apps improve well-being, mental health, and emotional regulation

RelatedReports

No obesity paradox found between BMI, stroke, and death
Cardiology

Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke

October 4, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

POINT trial: Clopidogrel and Aspirin for Acute Ischemic Stroke [Classics Series]

September 14, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

June 23, 2022
2 Minute Medicine Rewind October 14, 2019
Emergency

Patients with image-confirmed cerebral infarct have superior benefit from clopidogrel-aspirin therapy in preventing recurrent stroke

January 19, 2022
Next Post
2 Minute Medicine Rewind October 21, 2019

Mental health apps improve well-being, mental health, and emotional regulation

Quick Take: Hospital volume and outcomes for acute pulmonary embolism

The use of a diagnostic strategy with age-adjusted D-dimer thresholds was non-inferior in risk-stratifying for thromboembolic events in emergency department patients with suspected pulmonary embolism

American Academy of Pediatrics recommends standards for adverse event disclosures

2 Minute Medicine Rewind December 13, 2021

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options